A Novel Therapy for Staphyloccocal Enterotoxin B poisoning
治疗葡萄球菌肠毒素 B 中毒的新疗法
基本信息
- 批准号:7271825
- 负责人:
- 金额:$ 20.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-15 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAnimal ModelAntigensAttentionBioterrorismCategoriesClinical TrialsCoupledDrug FormulationsEatingEdible VaccinesEffectivenessEnterotoxinsFutureGlycine maxHumanImmune responseImmunityImmunizationLicensingMethodsModelingMucosal Immune ResponsesMusNorth CarolinaOralOral AdministrationOutcomePathologyPhasePhase II Clinical TrialsPlantsPoisoningProductionPurposeResearch PersonnelResourcesSeedsShippingShipsSmall Business Technology Transfer ResearchSourceSoy MilkSoybeansStaphylococcal Enterotoxin BStaphylococcal InfectionsSubunit VaccinesT-LymphocyteTechnologyTestingToxinTransgenic OrganismsTransgenic PlantsUniversitiesVaccinesWorkconceptcostefficacy trialimmunogenicitymouse modelmutantnoveloral vaccineprotein expressionresearch and developmentresponsesuccesstheories
项目摘要
DESCRIPTION (provided by applicant): Edible vaccines have received much attention since, in theory, they represent a source of vaccine that would stimulate mucosal immune responses, be cost-effective to produce, be safe to administer, and be stable to ship throughout the world. Studies proposed in this collaborative STTR effort will develop an oral vaccine against a non-toxic form of Staphylococcus enterotoxin B (SEB) by expressing this immunogen in transgenic soybeans. Completion of such studies will be significant since SEB has been identified as a potential agent of bioterrorism, and since no vaccine is presently available. Furthermore, once transgenic soybeans expressing a non-toxic form of enterotoxin B have been produced, these stably transfected plant lines will forever be a renewable source of this edible vaccine. A demonstration of the feasibility and efficacy of expressing an edible human vaccine against a non-toxic, mutant form of SEB in soybeans will be accomplished by performing the following specific aims. Specific aim #1: Expression of an immunogen, mutant SEB, in transgenic soybeans. The purpose of this aim is to characterize expression of a mutant form of SEB in soy milk formulations for use in an oral vaccine. Specific aim #2: To determine the efficacy of soybean-derived SEB as a mucosal immunogen following oral administration. In specific aim #2, we will address whether expression of SEB in transgenic soybean plants can elicit high levels of immunity following oral immunization of mice. Results from these studies will determine the magnitude of the B and T lymphocyte responses following administration of this edible vaccine. In addition, the ability of this edible vaccine formulation to protect against an SEB toxin challenge in a mouse model will be tested. Taken together, these studies will represent a significant, practical advance for the use of edible vaccines that are expressed in transgenic soybeans. In addition, the availability of this renewable resource will provide a product for future Phase II studies.
描述(由申请人提供):食用疫苗受到了广泛关注,因为从理论上讲,它们代表了一种疫苗来源,可以刺激粘膜免疫应答,生产成本低,给药安全,并且在世界范围内运输稳定。在这项合作STTR努力中提出的研究将通过在转基因大豆中表达这种免疫原来开发针对无毒形式的葡萄球菌肠毒素B(SE B)的口服疫苗。由于SEB已被确定为潜在的生物恐怖主义制剂,而且目前还没有疫苗,因此完成这些研究将具有重要意义。此外,一旦产生了表达无毒形式的肠毒素B的转基因大豆,这些稳定转染的植物系将永远是这种可食用疫苗的可再生来源。通过实施以下具体目标,将实现在大豆中表达针对SEB的无毒突变形式的可食用人疫苗的可行性和功效的证明。具体目标#1:在转基因大豆中表达免疫原突变体SEB。该目的的目的是表征SEB的突变形式在用于口服疫苗的豆奶制剂中的表达。具体目标#2:确定大豆来源的SEB作为粘膜免疫原在口服给药后的功效。在具体目标#2中,我们将解决在转基因大豆植物中表达SEB是否可以在小鼠口服免疫后引发高水平的免疫。这些研究的结果将确定接种该可食用疫苗后B和T淋巴细胞应答的幅度。此外,将测试该可食用疫苗制剂在小鼠模型中保护免受SEB毒素攻击的能力。总之,这些研究将代表一个重要的,实际的进展,使用可食用的疫苗,表达在转基因大豆。此外,这种可再生资源的可用性将为未来的第二阶段研究提供产品。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
Systemic cytokine and chemokine responses in immunized mice challenged with staphylococcal enterotoxin B.
用葡萄球菌肠毒素 B 攻击的免疫小鼠的全身细胞因子和趋化因子反应。
- DOI:10.1016/j.toxicon.2017.05.005
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:HudsonReichenberg,LauraC;Garg,Renu;Fernalld,Raymond;Bost,KennethL;Piller,KennethJ
- 通讯作者:Piller,KennethJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH J PILLER其他文献
KENNETH J PILLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH J PILLER', 18)}}的其他基金
Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
- 批准号:
10157209 - 财政年份:2021
- 资助金额:
$ 20.1万 - 项目类别:
Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
- 批准号:
10331867 - 财政年份:2021
- 资助金额:
$ 20.1万 - 项目类别:
Platform for practical delivery of oral autoantigens as co-therapies for neurological disease
口腔自身抗原作为神经系统疾病联合疗法的实际递送平台
- 批准号:
9341398 - 财政年份:2016
- 资助金额:
$ 20.1万 - 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
- 批准号:
7907500 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
- 批准号:
8591270 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
- 批准号:
8885710 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
- 批准号:
8692671 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
Efficacy of soybean-based vaccines using a model antigen
使用模型抗原的大豆疫苗的功效
- 批准号:
7256444 - 财政年份:2005
- 资助金额:
$ 20.1万 - 项目类别:
Efficacy of soybean-based vaccines using a model antigen
使用模型抗原的大豆疫苗的功效
- 批准号:
6926625 - 财政年份:2005
- 资助金额:
$ 20.1万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别: